Valneva SE filings document a foreign private issuer focused on prophylactic vaccines for infectious diseases. Its Form 6-K reports and Form 20-F disclosures cover consolidated financial results, product sales, research collaboration revenue, and business updates for marketed vaccines and clinical-stage programs, including Lyme disease, Shigella and chikungunya vaccine activities.
The filing record also includes material-event disclosures incorporated by reference into Form F-3 registration statements. These documents address material agreements, licensing and collaboration arrangements, capital-structure actions, shareholder voting and governance matters, risk factors, and clinical or regulatory updates for Valneva's vaccine candidates and commercial portfolio.
Valneva SE files a Form F-3 shelf registration to register up to 31,787,634 ordinary shares for resale by selling securityholders. The Resale Shares comprise up to 15,893,817 issued ordinary shares and up to 15,893,817 ordinary shares issuable upon exercise of ABSA Warrants.
The Resale Shares were issued in a private placement closed on May 5, 2026 under a Securities Purchase Agreement dated April 29, 2026, and Valneva will not receive proceeds from resale transactions, other than any cash received upon exercise of the ABSA Warrants (potentially up to €47 million if exercised in full). The ABSA Warrants include a Beneficial Ownership Limitation (default 9.99%, not to exceed 19.99% except as conditioned by French FDI rules).
Valneva SE, a specialty vaccine company, plans active investor outreach in June 2026 across the U.S. and Europe. Senior management will present and hold meetings at the Jefferies Global Healthcare Conference in New York, the Oddo BHF Nextcap Forum (virtual), and the BNP Paribas SMID Cap Conference in Paris.
Discussion topics include Valneva’s marketed travel vaccines and its pipeline, notably LB6V (formerly VLA15), described as the world’s leading Lyme disease vaccine candidate. LB6V is partnered with Pfizer, which reported topline Phase 3 results showing strong efficacy with no safety concerns and is planning regulatory submissions. Valneva will also engage travel medicine professionals as a Gold Sponsor and exhibitor at the NECTM10 conference in Belfast.
Valneva reported first quarter 2026 revenues of €30.9 million, down from €49.2 million a year earlier, as third‑party product sales were intentionally wound down and travel‑related demand softened. Product sales were €30.5 million, with IXIARO®/JESPECT® at €20.2 million, DUKORAL® at €8.6 million and IXCHIQ® at €1.6 million.
The company posted a net loss of €32.1 million versus a €9.2 million loss in 2025, and an adjusted EBITDA loss of €18.2 million. Profitability was hit by one‑off manufacturing and inventory charges, idle capacity and lower volumes, leading to weaker gross margins, especially for IXIARO®, DUKORAL® and IXCHIQ®.
Despite the larger loss, operating cash burn improved sharply, with net cash used in operating activities of only €0.3 million. Cash and cash equivalents were €105.3 million at March 31, 2026, excluding €37.0 million of gross proceeds from an April equity financing.
Valneva cut its 2026 product sales guidance to €135–150 million from €145–160 million, citing emerging adverse trends in travel vaccine uptake, but maintained other revenue expectations, giving total revenue guidance of €145–160 million. It launched a restructuring program, targeting a 10–15% global workforce reduction and an estimated 25–35% cut in 2026 operating expenses versus 2025.
In its pipeline, Lyme disease vaccine candidate LB6V showed more than 70% efficacy in a Phase 3 trial, with Pfizer planning regulatory submissions. For chikungunya vaccine IXCHIQ®, a pilot vaccination campaign in Brazil has already vaccinated over 30,000 adults, and local manufacturing was authorized by ANVISA. Shigella candidate S4V2 holds FDA Fast Track designation, with first Phase 2 results expected mid‑2026 and an estimated global market opportunity above $500 million.
Valneva SE’s major French shareholders have updated their disclosed stakes following new share issuance and recent trading. The filing shows that Bpifrance Participations now holds 7,158,835 Ordinary Shares and 14,317,670 voting rights, representing about 7% of Valneva’s voting rights as of May 5, 2026. CDC Croissance holds 4,755,872 Ordinary Shares and the same number of voting rights. Valneva completed a EUR84 million reserved offering of 15,893,817 new shares with attached warrants, which diluted these investors’ positions. Over the last 60 days, Bpifrance Participations sold 356,003 shares in open-market trades, while CDC Croissance bought 130,000 shares and sold 289,645 shares at disclosed weighted-average prices.
Frazier Life Sciences entities report beneficial ownership stakes in VALNEVA ordinary shares represented by American Depositary Shares.
Frazier Life Sciences Public Fund, L.P. (FLSPF) holds 3,623,582 Ordinary Shares (including ADS conversion). Frazier Life Sciences X, L.P. holds 115,500 Ordinary Shares; Frazier Life Sciences XI, L.P. holds 307,542 Ordinary Shares; Frazier Life Sciences XII, L.P. holds 536,708 Ordinary Shares. The filing cites 189,771,237 Ordinary Shares outstanding as of May 5, 2026. The reporting persons note prefunded warrants to acquire Ordinary Shares that are subject to a 9.99% beneficial ownership limitation.
Valneva SE, a specialty vaccine company listed on Nasdaq and Euronext Paris, announced it will report its first quarter 2026 consolidated financial results on May 13, 2026. The company will host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss the results and provide a business update.
The webcast will be accessible via Valneva’s website and an archived version will be available after the event. The filing also reiterates Valneva’s focus on developing and commercializing prophylactic vaccines, including its Lyme disease and Shigella vaccine candidates, and includes standard forward-looking statements language about development, regulatory, and partnership risks.
Valneva SE entered a private placement to raise approximately €37 million by issuing 15,893,817 new ordinary shares, each bundled with a warrant, at €2.33 per unit. If all attached warrants are exercised at €2.96 per share, the company could issue another 15,893,817 shares for about €47 million.
The warrants are exercisable for cash from shortly after issuance until the earlier of 30 days after FDA approval of Valneva’s investigational Lyme disease vaccine LB6V or just before March 31, 2028, with a possible extension to September 30, 2028 if approval is not obtained. Exercise is restricted by a “Beneficial Ownership Limitation” generally capped at 9.99%, adjustable up to 19.99% under conditions. Valneva granted investors registration rights for U.S. resale of the new and warrant shares, with deadlines to file and make effective a registration statement and cash liquidated damages of 1% of the invested amount per 30‑day delay period, subject to caps.
Valneva SE, a specialty vaccine company, reported that its leadership team will participate in multiple events at the 26th World Vaccine Congress in Washington, D.C., held from March 31 to April 2, 2026. Executives will present clinical updates and join a chikungunya-focused panel.
On April 1, 2026, Valneva’s Vice President Clinical Development, Susanne Eder-Lingelbach, will present on chikungunya vaccine development, including Phase IV and real-world evidence studies for its single-shot chikungunya vaccine IXCHIQ®. A pilot vaccination campaign in Brazil with partner Instituto Butantan has already vaccinated over 12,000 people.
Chief Medical Officer Dr. Juan Carlos Jaramillo will join a panel on chikungunya and mosquito-borne vaccines, while the company also meets partners and showcases at booth #538. Valneva highlights its broader pipeline, including a Lyme disease vaccine candidate with Pfizer and a Shigella vaccine candidate, alongside its marketed travel vaccines.
Valneva SE reported that PF-07307405 (LB6V), its Lyme disease vaccine candidate co-developed with Pfizer, showed more than 70% efficacy in the Phase 3 VALOR trial for people aged five and older. Pre-specified analyses found 73.2% efficacy from 28 days after the fourth dose and 74.8% efficacy from one day after the fourth dose, with no safety concerns identified at the time of analysis.
Because fewer Lyme disease cases occurred than expected, the first pre-specified analysis did not meet its statistical criterion. However, the second analysis did, giving Pfizer confidence to plan regulatory submissions for this investigational vaccine.
Valneva reported 2025 total revenues of €174.7 million, slightly above 2024, driven by higher IXIARO®/JESPECT® and IXCHIQ® sales and €16.8 million of collaboration and licensing revenue. Product sales were €157.9 million, with a planned 42.3% drop in third‑party sales but 9% proprietary growth at constant exchange rates.
The company posted a €115.2 million net loss, largely reflecting the absence of a €90.8 million one‑off gain from a 2024 Priority Review Voucher sale, and an adjusted EBITDA loss of €59.4 million. Cash stood at €109.7 million at year‑end, with operating cash burn reduced to €52.9 million.
For 2026, Valneva expects total revenues between €155 million and €170 million, including product sales of €145‑160 million, and plans further cash‑burn reduction while funding R&D. A potentially transformational Phase 3 readout for Lyme vaccine candidate VLA15 is expected in the first half of 2026, and first Phase 2 data for Shigella candidate S4V2 are expected mid‑2026.